Drug class profile · refreshed daily from federal data

Antimycobacterial

4 molecules in this class, $1.8M combined CY2024 Part D spend across 57K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Antimycobacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $1.8Mcombined across class
Total Rx claims: 57K23K unique beneficiaries
Generic mfrs (active): 8across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Pyrazinamide

4K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2020-07-27

3 generic mfrs 0 plans require PA

Low NADAC$1.45

→

Avg plan cost$1.45

Part D spend $932539 1× spread, current vs floor

Class share

53%

of class CY24 spend

View profile →

Isoniazid

53K Part D claims (CY24) · 20K beneficiaries · First FDA approval: 1972-09-01

5 generic mfrs 0 plans require PA Discontinued

Low NADAC$1.73

→

Avg plan cost$3.05

Part D spend $735222 2× spread, current vs floor

Class share

42%

of class CY24 spend

View profile →

Pretomanid

130 Part D claims (CY24) · 40 beneficiaries · First FDA approval: 2019-11-07

Brand-only (no generics) 27 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $96750

Class share

of class CY24 spend

View profile →

Pyrazinamide Tablet

Brand: PYRAZINAMIDE · — Part D claims (CY24) · First FDA approval: 2022-03-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.